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Abstract 
Background 
Magnetically Assisted Capsule Endoscopy (MACE) potentially offers a comfortable, patient 
friendly and community-based alternative to gastroscopy (EGD). This pilot study aims to 




The MiroCam Navi capsule system was used to examine the upper gastrointestinal tract in 
patients due to undergo a clinically indicated EGD. A total of 50 participants were enrolled, of 
which 34 had known pathology, 17 Barrett’s Esophagus (BE), 17 Esophageal Varices (EV), with 
16 controls. Patients underwent the MACE procedure, with the operator blinded to the 
indication and any previous endoscopic diagnoses. The subsequent EGD was performed by an 
endoscopist blinded to the MACE findings. Diagnostic yield, comfort and patient preference 
between the two modalities were compared. 
 
Results 
Participants had a mean age of 61 years old, a M: F of 2.1:1, a mean BMI of 29.5, with an 
average chest measurement of 105.3cms. 47 patients undertook both procedures, 3 patients 
were unable to swallow the capsule. With the use of the magnet, it was possible to hold the 
capsule within the esophagus for a mean duration of 190 secs and up to a maximum of 634 
secs. A correct real-time MACE diagnosis was made in 11/15 patients with EV (sensitivity 
73.3% (44.9- 92.2%) and specificity 100% (89.1- 100%) and 15/16 patients with BE (sensitivity 
93.8% (69.8- 99.8%) and a specificity of 100% (88.8- 100%). MACE was considered more 
comfortable than conventional endoscopy (p<0.0001) with a mean score of 9.2 with MACE 
compared to 6.7 with EGD, when assessed on a 10-point scale. No MACE or EGD related 
adverse events occurred. 
 
Conclusion 
This pilot study demonstrates that MACE is both safe and well tolerated by patients. Accuracy 
for the diagnosis of BE was high and may therefore have a role in screening for this condition.
Introduction 
Esophago-Gastro-Duodenoscopy (EGD) has become the ‘Gold Standard’ investigation of the 
Upper Gastro Intestinal (UGI) tract, allowing for direct mucosal inspection and where required 
therapeutic intervention. This is not without drawbacks, endoscopy is often regarded poorly 
amongst patients, with this test perceived as both invasive and uncomfortable (1,2). This 
diagnostic modality is resource intensive, requiring the use of a staffed and equipped 
endoscopy unit, as well as recovery facilities to enable the use of sedation. Growing demand 
and increasing strain on endoscopy departments, means that the development of a technique 
which takes procedures outside of the endoscopy department is an attractive proposition (3). 
 
Capsule endoscopy offers a comfortable and minimally invasive alternative to conventional 
endoscopy (4,5). The use of this technology beyond the small bowel is emerging (6). 
Examination of the UGI tract has thus far been limited by the rapid transit through the 
esophagus and the passive, undirected passage through the capacious stomach. With the use 
of a magnet within the capsule casing and an external magnet to manipulate movement, it is 
possible to overcome some of these obstacles to enable complete examination of the UGI 
tract.  
 
The MiroCam Navi, Magnetically Assisted Capsule Endoscopy (MACE) system (Intromedic, 
Soeul, South Korea) consists of a magnetic capsule which is steered using an external hand-
held magnet, allowing for portability (Figure 1). To date experimental studies have 
demonstrated non-inferiority compared to EGD in identifying markers within an ex-vivo 
porcine stomach as well as demonstrating  visualization of the major UGI landmarks within 
healthy volunteers (7,8). In this study we aim to determine the accuracy of MACE in the 
diagnosis of esophageal lesions. Secondary outcomes included patient comfort and 
preference, transit time and visualization of UGI landmarks. 
 
Methods 
Study design  
This was a prospective single blinded, diagnostic cohort study, performed at Nottingham 
University Hospital, following approval from the local Research and Innovation department 
(Ref: 16GA006). All procedures were performed between July 2016 and September 2017. 
Approval to conduct this study was obtained from the East Midlands Research Ethics 
Committee (Ref: 16/EM/0089) and prospectively registered on clinicaltrails.gov (Ref: 
NCT02852161).  
 
Sample size calculation 
To date studies concerning the use of MACE have focused on proof of concept, with limited 
information on diagnostic accuracy for lesions in the UGI tract. Accurate power calculations 
are therefore not possible at this time. This study has been designed as a feasibility study, 
which will then inform power calculations for future trials.  
 
For an observed sensitivity of 100%, a minimum of 17 patients were required in order to be 
able obtain confidence intervals that exclude a sensitivity below 80%. We therefore aimed to 
recruit 17 patients undergoing EGD for Barrett’s Esophagus surveillance (BE), 17 for 
Esophageal Varices surveillance (EV) and to ensure a realistic diagnostic assessment, 16 
controls without known esophageal lesions who were scheduled to undergo a clinically 
indicated EGD. Based on available imaging modalities a sensitivity of more that 80% for the 
detection of eith BE or EV would suggest that MACE may have a role in diagnosis. 
  
Patient selection 
Patients who were scheduled to undergo an EGD as part of the surveillance of known BE or 
EV were invited to participate in this study as cases. Those undergoing a clinically indicated 
EGD for the investigation of UGI symptoms were invited to participate as controls. Patients 
who satisfied the eligibility criteria were approached by the study coordinator, with the MACE 
operator blinded to the indication for the endoscopy or any previous results. Patients who 
had an implanted electronic or magnetic devices, were unable or unwilling to swallow the 
capsule or those with known dysphagia or obstructive bowel pathology were excluded from 
participation. Written informed consent was obtained from all participants. 
 
Interventions  
Both diagnostic tests were undertaken on the same day, by two independent operators 
blinded to the findings of the other modality. The MACE procedure was performed first, to 
avoid any artefact caused by scope trauma or biopsy acquisition during the EGD. 
 
Magnetically-assisted capsule endoscopy (MACE) 
The procedures were performed by a single endoscopist (SB) with experience in both the 
MACE procedure as well as conventional UGI endoscopy. As per standard pre-endoscopy 
preparation, patients underwent a 6-hour fast. Upon attendance for their procedure 
participants were instructed to consume approximately 1 litre of a solution consisting of 
water with six drops of simethicone (Infacol, Teva UK Ltd). Sensing pads were placed across 
the chest to enable the transmission of images from the capsule. Once lying supine, with the 
head raised at a 10-degree angle, the patient was instructed to place the capsule in the 
mouth, and then to swallow the tablet alongside water sipped through a straw. This reclined 
position was adopted to optimise the capsule transit time through the esophagus. The hand-
held magnet was held above the sternum in order to catch the capsule within the esophagus. 
Real time images were viewed using a tablet equipped with proprietary MiroCam software. 
Changes in patient posture and placement of the handheld magnet were used to manipulate 
the capsule in order to enable examination of the esophagus and stomach, as described in 
previous studies (7). The capsule was held in the esophagus for as long as possible, successful 
oesophageal capture was defined as a transit time greater than 30 seconds, double the 
median transit of a non- magnetic capsule swallowed whilst recumbent (REF). Once adequate 
images of the had been obtained of the upper GI tract or the maximum examination time of 
20 minutes had been reached, the capsule was released in the region of the pylorus and 
allowed to pass into the small bowel. Any abnormalities detected during the real time 
examination were documented on a Clinical Record Form (CRF) contemporaneously. The 
quality of views obtained at each of the major land marks was assessed by the operator using 
a 5-point scale (where 0 denotes the landmark was not visualised and 4 denotes complete 
views obtained (Appendix 1). A period of at least one hour was given between undergoing 
the MACE and EGD, in order to allow the intra-gastric volume of water to reach its resting 
volume of 35mls (9). The capsule sensing device was removed following completion of both 
the MACE and EGD procedures, with the capsule left to passively transit through the GI tract. 
As such recordings of the capsule reaching the caecum were not obtained. Where the patient 
had not visually identified excretion of the capsule by two weeks post procedure an xray was 
performed to exclude retention. 
Esophago-Gastro-Duodenoscopy (EGD) 
EGDs were performed by experienced endoscopists, certified for independent practice. These 
practitioners were aware of any findings from previous endoscopies and the indication for 
the procedure, but not the findings of the prior MACE procedure. The EGDs were performed 
using standard techniques, with no biopsies or interventions specifically performed as part of 
this study. Patients had the option of pharyngeal anaesthesia or intravenous sedation, with 
the requirement for post procedure recovery determined by this choice. Findings were 
ascertained by the performing endoscopist at the time of the procedure and documented on 




A series of patient comfort and anxiety questionnaires were completed throughout the 
course of this intervention. These were carried out prior to any intervention, following the 
MACE procedure, following the EGD and finally two weeks following participation. Patients 
were provided with a prepaid addressed envelope in order to return the two-week 
questionnaire. Where questionnaires were not returned, the study coordinator contacted the 
patient by phone as a reminder within three weeks. The questionnaires included a visual 
analogue scale to assess overall procedure tolerability (0- 10 scale, where 10 denotes the best 
possible experience), with separate scores recorded for specific symptoms, including gagging, 
choking or pain incurred.  
 
Image review and inter-observer agreement  
Recordings of both the MACE and EGD procedures were taken with patient permission. 
Anonymised endoscopic images were reviewed without clinical information by five 
endoscopists, to establish whether diagnoses could be accurately determined post 
procedure. The real time diagnosis made at EGD was considered to be the gold standard for 
comparison. Video clips were edited to include the esophageal images only, with any 
interventions or enhanced imaging techniques (such as the use of Narrow Band Imaging) 
performed during the EGD edited out to render the images comparable with those obtained 
during the MACE procedure.  
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism, Version 7 and Stata Version 15. A p-
value of less than 0.05 was considered statistically significant. Normally distributed data were 
compared using paired t-tests, while non-normally distributed data were compared using 
Wilcoxon signed rank test. We examined the ralationships of esophageal transit time to 
factors which might influence it via spearman’s rank correlation for continuous variables and 
Kruskal Wallis test for non-continuous variables. Proportions were compared using Chi 
Squared test. Sensitivity and specificity of diagnoses made by MACE were calculated based 
on EGD diagnosis being the gold standard. The intra-observer agreement in the recorded EGD 
and MACE images was determined using method of (Fleiss, Levin, and Paik 2003,p 615) to 






50 patients were recruited into the study, of which 47 (94%) completed the MACE procedure 
and 50 (100%) completed the EGD. As per the recruitment criteria these were composed of 
patients with endoscopically diagnosed BE (17), EV (17) and patients with neither BE or EV 
(16).  In those with EV endoscopy graded these as large in 100% of cases, whilst in those with 
BE the average Barrett’s segment legnth was 3 cms (2-5), with 22 patients diagnosed with a 
hiatus hernia. The recruitment process and baseline characteristics of the study cohort are 
summarised below (Table 1 and Figure 2). 
Table 1. The baseline characteristics of study participants  
Data presented as number (%) or mean (+/- SD) or median (IQR)  
Characteristic Number or mean (range)  
Gender distribution Male 34 
Female 16 
Age (years) 60.5 (39-83) 
Body Mass Index 29.5 
Dimensions (cms) Chest  104 (86-127) 
 Waist  105 (63- 133) 
 Hip  103 (92- 141) 
Indication for 
procedure 
Variceal surveillance 17 
Variceal screening 1 
Barrett’s surveillance 18* 
Gastro-Intestinal bleeding 3 
Dyspepsia / pain 7 
UGI surveillance 4 
Number of previous of EGDs (for any indication) 2.5 (0 - 12) 
*One patient who was recruited in the Barrett’s group did not have Barrett’s on EGD and 
was therefore moved to the control group for the purpose of analysis. 
 
Feasibility  
All 50 patients were able to undertake the EGD. It was however noted that 45% opted to have 
sedation, with a median dose of 3mg of midazolam and 50mg of pethidine administered. Of 
the 50 patients recruited, three patients were unable to undertake the MACE procedure. In 
all cases this was due to being unable to swallow the capsule whilst supine, despite having no 
known swallowing disorders. All three managed to tolerate their EGD with the use of sedation 
in tw of these patients.   
 
Tolerance and patient preference 
The MACE procedure rated more favourably than EGD for all comfort related domains. The 
mean VAS associated with MACE was 9.4, compared to 6.6 with EGD (P<0.0001). This trend 
persisted even when the use of sedation prior to EGD was taken in to account (Table 2). 
Further, MACE was considered more comfortable for each of the specific symptoms recorded, 
gagging, choking and discomfort. Participants who completed the two-week questionnaire 
(37 of 47 participants) preferred to undergo the MACE procedure, should they require a 







Table 2. Comfort and tolerability of procedures 
Expressed as median and Interquartile Range or Mean and Standard Deviation 
 













10 (IQR 4.0-10) 4 (IQR 1.0- 6.2) 0.0001 
Choking 
 
10 (IQR 10-10) 6 (IQR 0.8-10) <0.0001 
Discomfort 
 















All patients (n=50) 9.2 (SD +/-1.6) 6.7 (SD +/- 2.6) <0.0001 
Sedated cohort 
(n=33) 
9.4 (SD +/- 1.1) 6.6 (SD +/- 2.6) <0.0001 
Unsedated Cohort 
(n=17) 







  Preferred procedure 
at 2 weeks 
27/37 0/37  
 
Capsule manipulation within the esophagus 
Of the 47 patients who successfully swallowed the capsule, the esophagus was visualised in 
all cases. Control of the capsule was variable, with a mean esophageal transit time of 190secs, 
(range: 5secs- 634secs). The capsule was held within the esophagus for 30 seconds or more 
in 68% (n=32). It was not possible to identify any operator or patient factors which influenced 
esophageal transit time (Table 3). There was a non-significant trend towards increased transit 
time in association with increased operator experience as the study progressed, R=0.13 (CI -
0.17- 0.41) p=0.39.  
 
Table 3. Regression model examining factors with the potential to influence esopahegal 
transit time 
  Observations Rank sum P-Value 
Gender Male 31 791.50  
 Female 16 336.50 0.29 
Condition Barrett’s 16 369.50  
 Varices 15 364.00  
 Controls 16 394.50 0.95 
 Correlation 
coefficient 
P- Value   
Age -0.09 0.55   
BMI -0.09 0.55   
Chest Circumference -0.13 0.40   
Case order 0.13 0.39   
 
Capsule manipulation within the stomach 
Complete visualisation of the stomach was attempted through a combination of position 
changes and use of the hand-held magnet. As demonstrated in previous studies, the fundus 
remains a potential blind spot during the MACE procedure, with EGD quality of views 
significantly superior (Table 4). This study was not powered to calculate the ability to detect 
gastric pathology, however 2 lesions seen on EGD were not seen on MACE, whilst 1 lesion was 
missed by EGD. 
 






































0/50 P = 0.0803 
 
-2.18 - 16.65 
  
z- line  8/47 0/50 
 
P = 0.0013 
 






P = 0.0001 
 
13.41 - 40.01 
 
  
Body  5/47 
 
0/50 P = 0.0165 
 
1.58 - 23.04 
  
Antrum 3/47 0/50 
 
P = 0.0803 
 
-2.18 - 16.65 
  
Capsule manipulation into the duodenum 
The magnet could not be used to transfer the capsule from the stomach into the duodenum. 
When the MACE examination was complete, the capsule was placed within close proximity of 
the pylorus, but it was not possible to overcome pyloric contractions in order traverse the 
pylorus. For logistical reasons the sensing equipment had to be removed early in 4 cases, the 
capsule was left to transit through the small bowel, but was not observed to transit in to the 
duodenum during the shorter recording.  Amongst the 43 cases where the duodenum was 
entered during recording, a mean gastric transit time of 35 mins (range: 2 mins- 2 hours 17 
mins) was observed. This is consistent with a previous study, where it was concluded that the 
MACE system could not be used to reduce the gastric transit time, reporting an average 
passage of 35.5 minutes (10). Active small bowel bleeding was diagnosed on capsule following 
the MACE in one patient, which was beyond the extent of the EGD. 
 
Accuracy in detection of esophageal lesions 
 
With the use of MACE, it was possible to make a correct real-time diagnosis in 15 of the 16 
cases of Barrett’s Esophagus, with no false positives. Where Esophageal Varices were present, 
MACE was able to diagnose these in 11 out of the 15 cases, with no false positives. Esophageal 
lesions other than Barrett’s or Varices, were seen in 3 cases. This included one inlet patch and 











Table 5. Accuracy in detection of esophageal lesions 
 Sensitivity Specificity 
Detection of Barrett’s 93.8% (69.8- 99.8%) 100% (88.8- 100%) 
Detection of  
Varices 
86.7% (59.5- 98.3%) 100% (89.1- 100%) 
Detection of esophageal 
lesions 




Intra-observer variability  
We examined intraobserver variability by the post procedural review of the videos of both 
the EGD and MACE. These were reviewed by 5 endoscopists, all of whom are certified to be 
independent in UGI endoscopy but had no specific training in the interpretation of UGI 
capsule endoscopy. The Kappa values for each condition using either modality is summarised 
in Table 6. 
 
Table 6. Interobserver variability in diagnosis of post procedural review of  MACE and 
EGD images. 
 MACE EGD 
Kappa SE P value Kappa SE P value 
Barretts 
Esophagus 
0.67 0.08 0.00 0.72 0.08 0.00 
Esophageal 
Varices 
0.46 0.08 0.00 0.39 0.08 0.00 
Controls 
 




The results from this study suggest that MACE is both technically feasible and safe. Accuracy 
in the diagnosis of esophageal lesions as compared with EGD was reasonable. Patients 
reported high levels of comfort, preferring this investigative modality over EGD. No procedure 
related adverse events were encountered. 
 
There was a difference in technical success of -6% (94% with MACE versus 100% with EGD). 
This initial experience compares with published data suggesting a technical success of 
esophageal intubation of 99% with EGD (with the use  sedation if required) (11),  96- 99% with 
unsedated trans-nasal endoscopy (12,13), 93.9% using the cytosponge (14) and 98% and with 
a dedicated esophageal capsule (15). 
 
Once swallowed, it was possible to control the capsule within the esophagus, as 
demonstrated by the median and mean esophageal transit time of 163 and 190 secs 
respectively. This compares favourably with a previous study of a non-magnetic esophageal 
specific capsule, which demonstrated an average esophageal transit time of 14 secs (95% CI 
4 to 86 secs) when ingested in a supine position, or of just 3 secs (95% CI 3 to 8secs) when the 
patients were standing at the time of ingestion (15). It not clear as to why there was a wide 
range in oesophageal transit time with the MACE system. We attempted to elucidate whether 
factors such as operator experience or patient characteristics were influential, however failed 
to reveal a significant trend. The shorter transit is likely as a result of propagatory oesophageal 
forces overcoming the forces between the magnetic attraction between hand held magnet 
and capsule, the former which can reach >180mm/hg. 
Despite in some cases a rapid transit through the esophagus, the GEJ was visualised in 100% 
and the z-line in 91.5%. It is possible that this could be improved further with modifications in 
capsule design, with the esophageal capsule offered by PillCam ESO3 (Medtronic, Minnesotta 
USA) taking up to 35 images per second. Were this modification to be applied, this could result 
in an average of 5130 additional esophageal images acquired per patient in our study cohort.  
 
Patient comfort scores demonstrated a preference of MACE over EGD. This remained the case 
even where sedation was given prior to performing the EGD. This corroborates previous 
studies, where capsule visualisation has been used as an alternative where patients have 
declined flexible endoscopy (5).  However, its is appreciated that MACE was not performed 
on all comers and as such those more likely to have higher anxiety levels or report discomfort 
may have been selected out in the recruitment process. From this study design it is not 
possible to ascertain whether improved comfort would result in greater uptake rates. 
 
In this pilot study, we were able to demonstrate a reasonable accuracy for the detection of 
esophageal lesions, although at present insufficient to replace conventional endoscopy for 
diagnosis. Our data compares to previous studies using either a string-capsule or the 
dedicated esophageal capsule, which report an accuracy in the diagnosis of EV  of  86% (range: 
77%- 96%)  (16–21). We demonstrated better sensitivity for the presence of Barrett’s than 
was seen with these older technologies, pooled sensitivity of 86% c.f. 93.8%  in the current 
study (22) 
 
Implications for clinical practice 
There is increasing interest in developing minimally invasive, community-based techniques 
for investigation of the UGI tract. MACE meets this brief, with the additional value of providing 
pan-endoscopy within a single procedure.  The current cost of capsule equipment has thus 
far been prohibitive for routine use. However this may be offset with the potential of 
performing this procedure with the aid of non-medical endoscopists or physician extenders 
and within the community setting without the requirement for sedation or decontamination 
equipment (23). Whilst capsule endoscopy does not allow for the acquisition of histological 
samples, it is known that the majority of EGDs are diagnostic with no requirement for biopsies 
or intervention for many indications, with as many as 78% of those undergoing endoscopy for 
dyspepsia demonstrating no mucosal abnormalities (24). With a high negative predictive 
value UGI capsule could be regarded as a scouting technique, in order to detect those with 
major pathology or with pre-malignant change, who warrant more detailed assessment with 
advanced imaging or the acquisition of histology. 
 
This technology exists within an environment that includes alternatives such as trans-nasal 
endoscopy and esophageal capsule, as well as non-endoscopic techniques such as the 
cytosponge. Limitations of the ESO capsule include its short battery life, which limits imaging 
to the esophagus and stomach. The Cytosponge allows for the acquisition of cytological 
specimens to evaluate specific esophageal pathology, but no endoscopic images and with 
evaluation limited to the esophagus (14,25). Unsedated nasal endoscopy is perhaps the most 
comparable modality being performed in the community, with no sedation and high levels of 
patient acceptability. Further on in its development, there has been an improvement in the 
quality of images obtained and high levels of diagnostic accuracy demonstrated (12,26–28).  
Specific benefits of MACE would be in those who have a condition which would benefit from 
pan endoscopy, such as those being investigated for iron deficiency ananemia or in those who 
decline flexible endoscopy.  Further developments in the field of MACE include automation, 
the Ankon system (Ankon Optoelectronic Technology Co. Ltd, China) utilizes a computer 
controlled robotic arm, which can be either directly controlled or adopt a pattern of 
programmed movements. This has been used in a variety of populations, with promising 
results (29–32). There are no direct comparisons between this robotically controlled system 
and the MiroCam Navi system, however studies using these systems that  examined the ability 
to pull the capsule past the pylorus, suggested whilst this was not possible with a hand held 
magenet it could be achieved with the Ankon system, suggesting stronger or more effective 
magnetic capture (10,33).   
Study strengths and limitations 
This study was conducted within a single centre, with all MACE procedures performed by a 
single operator. While this ensures consistency in technique and environment, the 
reproducibility of these results outside of this setting is unknown.  
 
The endoscopic diagnosis made from the MACE procedures were made in real time. The 
operator was not blinded to the appearances of the patient. Given that a proportion of the 
participants had underlying liver disease it could be argued that the phenotype of these 
patients may influence the operator of the pre-test suspicion of esophageal varices. This 
potential bias is thought to be of minimal influence, given that the control cohort included 
patients with suspected EV and BE, which were correctly diagnosed as normal at both EGD 
and MACE.  Additionally review of the post procedural images demonstrated similar Kappa 
Values for both MACE and EGD. Similiarly, a potential bias in favor of conventional endoscopy 
was introduced, with the possibility of reviewing previous endoscopy reports and being aware 
of the indication pre-procedure, compared to the blinded performance of MACE. The choice 
for this approach was a pragmatic one, in our institution BE and EV are placed on specialist 
lists and as such we did not want to deviate from standard practice in conventional endoscopy 
for participants. Unanswered questions include whether the results of the MACE procedure 
would be as promising in an unselected population with a wider variation of pathology, in 





The findings from this pilot study demonstrate that the MACE procedure is safe and well 
tolerated by patients. Acceptable accuracy was demonstrated for the diagnosis of esophageal 
lesions but this will require validation through larger studies. There is scope to optimize the 
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Appendix 1: Visulaisation grading system of upper gastro intestinal landmarks.  
Grade Description 
0 No image obtained 
1 Poor quality views with less than 50% visualization of the landmark. 
2 Reasonable quality views with approximately 50% visualization of the 
landmark 
3 Good quality views with approximately 75%  visualization of the landmark 
4 Excellent quality views with 100% visualization of the landmark 
 
Figure 1: The components of the MiroCam Navi MACE system 
A.  Hand held Magnet: 26 cm x 3.5 cm hand held magnet. 
B.  Computer: Real time and saved images of the MACE procedure can be viewed using a tablet or laptop with 
proprietary MiroCam interpretation software.  
C. Magnetically Steerable Capsule : 11x 24mm capsule, with a weight of 4.2g. Images are obtained at a rate of 
3 frames per second at a resolution of 320 x 320. The capsule has a field of view of 170 degrees and depth 
of field of 30mm.  
D. Sensing system: The sensing system consists of 9 sensing pads that are placed at pre-designated points across the 
torso. Images are transmitted from the sensing box to a computer using Wi-Fi, allowing real time assessment. 
 
Figure 2. A flow diagram summarising study recruitment 
Figure 3. Example pictures of esophageal lesions detected on MACE 
A & B: Esophageal Varices  
C&B: Barrett’s Esophagus 
E: Esophagitis above a Barrett’s segment F: Cervical Inlet Patch 
 
Figure 4. Example pictures of non-Esophageal lesions detected on MACE  
A&B Portal hypertensive gastropathy 
C: Gastric angioectasia D: Gastric polyp 
E: Duodenitis F: Active small bowel bleed 
 
 
